NFKB1 and neoplasm: On the other side, in the light of the multiple functions of NF-κB in the innate and adaptive immune responses, the use of NF-κB inhibitors would not be recommended to treat malignancies, especially in the tumour-eliminating phase, when immune cells specifically target transformed cells.